Tough second half takes its toll on Huon

Published 15-AUG-2018 10:58 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Name: Huon Aquaculture Group Ltd (ASX:HUO)

Market Capitalisation: $412 million

Opening Share Price: $4.72

Despite delivering a record operating net profit of $35.4 million for fiscal 2018, salmon producer Huon Aquaculture’s result has fallen short of expectations.

Analysts at Ord Minnett were forecasting a net profit of $39 million and a full year dividend of 15 cents per share.

While the full year dividend of 10 cents per share was well short of the broker’s expectations, it should be noted that consensus dividend forecasts of 12.8 cents per share didn’t reflect such a significant shortfall.

It is worth digging below the headline figures in terms of assessing the result as the company delivered a record harvest tonnage and achieved strong pricing in a healthy supply/demand market.

Growing conditions impact production

Difficult growing conditions prevailed in the second half of fiscal 2018, and management said that this situation has continued to impact the group.

Consequently, Huon has commenced fiscal 2019 with a lower biomass than had been projected.

While the company anticipates a fiscal 2019 harvest volume of circa 20,000 tonnes, below the record level achieved in FY2018, stronger pricing is expected to deliver continued growth in operating EBITDA.

Beyond fiscal 2019 management expects Huon to return to production levels in line with the market’s long term average growth of approximately 10%.

This outcome, supported by market expectations that pricing will continue to be underpinned by the shortage of supply over demand, should deliver continued growth in operating EBITDA in FY2020.

However, whether the medium to long-term outlook is enough to appease the market remains to be seen, so investors should seek professional financial advice if considering this stock for their portfolio.

With the company trading on a trailing PE multiple of 15.6 there is little room for underperformance.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free